Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEZ235 Monotherapy in HR+ HER2- Metastatic Breast Cancer
NCT01288092Phase 2Withdrawn
- Sponsor
- Novartis
- Start
- Mar 2012
- Primary completion
- Sep 2015
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of dactolisib in breast cancer, sponsored by Novartis. Primary endpoint: Progression-free survival rate at 16 weeks. Planned start Mar 2012; status: withdrawn.
02
Drugs
dactolisib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01288092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01288092.